Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS

References

• Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 2. Endocr Pract 2015;21:1415–1426.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007;30:228–233.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Yildiz BO. Insulin resistance in polycystic ovary syndrome: maker or marker? Expert Rev Obstet Gynecol 2010;5:67–75.
   Google Scholar
• DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:1615–1622.
   PubMed Web of Science ®Google Scholar
• Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97:18–22.
   PubMed Web of Science ®Google Scholar
• Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152:673–684.
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51:2796–2803.
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517–522.
   PubMed Web of Science ®Google Scholar
• Hedblad B, Nilsson P, Janzon L, et al. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000;17:299–307.
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539–548.
   PubMed Web of Science ®Google Scholar
• Mari A, Pacini G, Brazzale AR, et al. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005;48:748–751.
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936–1940.
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G. Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 1997;273:E701–E707.
   PubMed Web of Science ®Google Scholar
• Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116–128.
   PubMedGoogle Scholar
• Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569–574.
   PubMed Web of Science ®Google Scholar
• Saisho Y, Kou K, Tanaka K, et al. Association between beta cell function and future glycemic control in patients with type 2 diabetes. Endocr J 2013;60:517–523.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab 2013;24:145–152.
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endo Dis 2009;9:17.
   PubMed Web of Science ®Google Scholar
• Holland DQ, Neumiller JJ. Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014;7:277–288.
   PubMedGoogle Scholar
• Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care 2010;33:2406–2408.
   PubMed Web of Science ®Google Scholar
• Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007;76:163–176.
   PubMed Web of Science ®Google Scholar
• Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol 2014;170:565–574.
   PubMed Web of Science ®Google Scholar
• van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 2012;14:101–111.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871–E883.
   PubMed Web of Science ®Google Scholar
• Valsamakis G, Lois K, Kumar S, et al. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). Hormones (Athens) 2013;12:363–378.
   PubMedGoogle Scholar
• Glintborg D, Hojlund K, Andersen M, et al. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31:328–334.
   PubMed Web of Science ®Google Scholar
• Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210–1218.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Hagen C, et al. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. Fertil Steril 2009;91:842–850.
   PubMed Web of Science ®Google Scholar
• Coffler MS, Patel K, Dahan MH, et al. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;88:5624–5631.
   PubMed Web of Science ®Google Scholar
• Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. J Biol Chem 2001;276:16767–16771.
   PubMed Web of Science ®Google Scholar
• Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005;25:244–252.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;94:469–476.
   PubMed Web of Science ®Google Scholar
• Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3835–3840.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 2006;86:385–397.
   PubMed Web of Science ®Google Scholar
• Gambineri A, Semple RK, Forlani G, et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol 2008;159:347–353.
   PubMed Web of Science ®Google Scholar
• Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study. Lancet 2010;376:103–111.
   PubMed Web of Science ®Google Scholar